YMTX - Yumanity Therapeutics GAAP EPS of -$3.84 revenue of $8.04M
Yumanity Therapeutics press release (NASDAQ:YMTX): FY GAAP EPS of -$3.84. Collaboration Revenue of $8.04M (+16.5% Y/Y). As of December 31, 2021, cash, cash equivalents and investments were $36.5 million.
For further details see:
Yumanity Therapeutics GAAP EPS of -$3.84, revenue of $8.04M